In early December 2025, Denali Therapeutics announced a US$275 million synthetic royalty funding agreement with Royalty Pharma tied to future worldwide net sales of its investigational Hunter syndrome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback